Your Health, We Care
Release date: 2026-05-27 15:58:52 Article From: Lucius Laos Recommended: 17
Tivozanib (generic name: tivozanib) is a prescription medicine used to treat adults with advanced kidney cancer (also known as advanced renal cell carcinoma, RCC) that has come back or has not improved after two or more prior treatments. It is the first and only vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI) approved for this indication. The drug works by inhibiting tumor blood vessel growth, thereby controlling the growth and spread of cancer cells.
If you have been diagnosed with recurrent or metastatic kidney cancer and the current medication is no longer working, it means your cancer is in a "refractory" state. In this case, Tivozanib can be considered as a subsequent treatment option. You should have an open and honest discussion with your healthcare provider to find out if this drug is appropriate for you. Tivozanib is specifically intended for patients who have already tried at least two prior treatments (including immunotherapy or other TKIs) but have still experienced disease progression.
Taking Tivozanib is very convenient: one capsule once a day, swallowed with a glass of water, with or without food. The standard treatment cycle consists of 21 consecutive days of dosing followed by 7 days off, forming a complete 28-day cycle. Be sure to follow your healthcare provider's instructions exactly, and do not adjust the dose or stop taking the medicine on your own. This "three weeks on, one week off" design helps balance efficacy with the body's tolerability, allowing patients to better integrate it into their daily lives.
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended：3782025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended：5702024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended：3592025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended：3732025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended：3492025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended：4202025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended：3402025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended：3162025-27-11
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address: No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Name: Lucius
Telegram name: Vira
No.:0085253923643
Telegram name: Vira
No.:0085253923643
